Key Takeaways

A BMJ guideline put patient risk into the equation for assessing the suitability of SGLT-2 inhibitors and GLP-1 receptor agonist drugs for type 2 diabetes.

Their use in type 2 diabetes was only strongly recommended for people at higher risk of cardiovascular and kidney complications.

Meanwhile, these costly medications continue to be used more and more in the U.S. for a variety of indications.

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ panel.

In a new "living" guideline, intended to keep pace with the rapidly growing evidence base for these emerging drugs, an international expert group said that SGLT2 inhibitors and

See Full Page